Neovasc announced publication of data from the REDUCE study of the Neovasc Reducer for refractory angina in the International Journal...
The coronary sinus (CS) Reducer is a novel device designed to aid in the management and to improve quality of life of patients with severe angina symptoms refractory to optimal medical and interventional therapies.
Neovasc Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...
Shockwave Medical, Inc. a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease,announced the completion of its previously announced acquisition of Neovasc Inc.
Neovasc Inc. announced that the FDA’s Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc Reducer is safe when used as intended, and voted 1 to 17 “against” on the issue of a reasonable assurance of effectiveness.
Seventh Sense Biosystems, a privately held health technology company developing a breakthrough painless diagnostic blood collection platform, initiated a pivotal...
SGLT2 Inhibitors: good news for diabetes Within the last 3 years, the biggest development in treatment options for Type 2...
Giving a daily Truvada (emtricitabine/tenofovir disoproxil fumarate) pill to help prevent HIV infection could significantly reduce the spread of AIDS,...